Curtis E. Haas, PharmD, FCCP, Pharmacy Times Directions in Health-System Pharmacy Editor-in-Chief

For many years, employers, payers, and pharmacy benefit managers have been developing benefit designs to incentivize patients and providers to make cost-effective treatment decisions.

Maximizer programs are likely to lead to the dwindling or death of PAPs as we know them.

Pharmacists should be vocal in objecting to unproven therapies for COVID-19 being widely used primarily based on wishful thinking.

Consider these 5 takeaways from a pharmacy leader in an academic health care system during the COVID-19 crisis.

A more reasonable way to address shortages: price drugs at a level that provides incentive to ensure a consistent, high-quality supply.

Health System Pharmacists Should Think About the Implications of Acquiring and Dispensing These Compounded Products.